Want to see AKTX full AI Analyst Report?
AKTX Stock Chart & Stats
$8.70
-$0.24(-2.76%)
At close: 4:00 PM EDT
$8.70
-$0.24(-2.76%)
Day’s Range― - ―
52-Week Range$3.02 - $49.60
Previous Close$8.46
Volume52.72K
Average Volume (3M)1.63M
Market Cap
$9.00M
Enterprise Value$5.55
Total Cash (Recent Filing)$2.77M
Total Debt (Recent Filing)$732.00K
Price to Earnings (P/E)―
Beta1.54
Next Earnings
May 20, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1448.00
Shares Outstanding1,144,588
10 Day Avg. Volume2,851,768
30 Day Avg. Volume1,628,756
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.50Price Target Upside227.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.77
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageAkari's very low reported debt load reduces near-term solvency risk and preserves financial flexibility. For a pre-commercial biotech with ongoing R&D, low leverage lowers mandatory interest and repayment burdens, making future dilutive financing or strategic partnering decisions less constrained by creditor covenants.
Proven Access To CapitalThe completed and amended private placement demonstrates the company's ability to secure institutional financing when needed, extending operational runway. Durable access to accredited-investor capital is essential for clinical-stage biotechs to fund trials and regulatory activities absent product revenue.
Capital-Structure FlexibilityShareholder approval of long-duration allotment authority and waiver of pre-emption rights provides structural flexibility to raise equity, issue warrants, or pursue strategic transactions over time. This governance backing reduces execution risk for future financings or partner-aligned equity issuances.
Bears Say
No RevenueThe company remains pre-revenue, meaning all value depends on successful R&D and regulatory outcomes. Without product sales, Akari must repeatedly access capital to fund operations; commercial execution risks and clinical trial failures would directly erode valuation and could sharply curtail its ability to continue programs.
Persistent Cash BurnSustained negative operating and free cash flow imply recurring financing needs. Even with recent improvement, ongoing cash burn drives dilution risk and limits optionality for expanding programs or hiring. Funding cycles dominate strategic choices and can force prioritization or program cuts if capital access tightens.
Eroding Equity BaseMaterial equity erosion reflects cumulative losses and recurring dilution, weakening the company's balance-sheet buffer. A smaller equity base reduces shock absorption for adverse trial or regulatory outcomes, increases sensitivity to additional financings, and signals that current capital may be insufficient to sustain long-term program development without further raises.
Akari Therapeutics News
AKTX FAQ
What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $3.02 and its highest was $49.60 in the past 12 months.
What is Akari Therapeutics’s market cap?
Akari Therapeutics’s market cap is $9.00M.
When is Akari Therapeutics’s upcoming earnings report date?
Akari Therapeutics’s upcoming earnings report date is May 20, 2027 which is in 288 days.
How were Akari Therapeutics’s earnings last quarter?
Currently, no data Available
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Undervalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 1,144,588 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in AKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akari Therapeutics
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
AKTX Stock 12 Month Forecast
Average Price Target
$28.50
▲(227.59% Upside)
Technical Analysis
Ownership Overview
25.66% Insiders
7.32% Other Institutional Investors
67.02% Public Companies and
Individual Investors